darunavir vs sofosbuvir/velpatasvir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of darunavir and sofosbuvir/velpatasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.4 Drugs without Clinically Significant Interactions with VOSEVI Based on drug interaction studies conducted with the components of VOSEVI (sofosbuvir, velpatasvir, and/or voxilaprevir) or VOSEVI, no clinically significant drug interactions have been observed with the following drugs [see Clinical Pharmacology (12.3) ]: VOSEVI: cobicistat, darunavir, elvitegravir, emtricitabine, ethinyl estradiol/norgestimate, gemfibrozil, rilpivirine, ritonavir, tenofovir alafenamide, voriconazole Sofosbuvir/velpatasvir: dolutegravir, ketoconazole, raltegravir Sofosbuvir: methadone, tacrolimus
Prezista
Epclusa
Darunavir is a medicine used to treat HIV. It belongs to a class of drugs called protease inhibitors and must be taken with ritonavir.
Vosevi is a drug that combines three medicines into one tablet. It is used to treat hepatitis C in adults who have already tried other treatments.
Darunavir is used to treat HIV-1 infection in adults and children 3 years and older. It must be taken with ritonavir and other HIV medicines. Darunavir helps to lower the amount of HIV in your body.
Vosevi treats chronic hepatitis C (HCV) infection in adults. It is for those without cirrhosis or with compensated cirrhosis (Child-Pugh A). You can use it if you have genotype 1, 2, 3, 4, 5, or 6 HCV. You must have already been treated with a hepatitis C medicine containing an NS5A inhibitor, or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).
Darunavir is a protease inhibitor. It works by blocking an enzyme called protease that HIV needs to make copies of itself. This helps to slow down the spread of HIV in your body.
Vosevi contains sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir blocks a protein called NS5B polymerase that the hepatitis C virus needs to multiply. Velpatasvir blocks the NS5A protein, and voxilaprevir blocks the NS3/4A protease protein, both of which the virus also needs.
- • Diarrhea
- • Nausea
- • Rash
- • Headache
- • Abdominal pain
- • Headache
- • Fatigue (feeling tired)
- • Diarrhea
- • Nausea (feeling sick to your stomach)
- Foetal Exposure During Pregnancy 1,150
- Drug Interaction 981
- Pain 889
- Emotional Distress 812
- Anxiety 811
- Feeling tired 2,307
- Hepatitis C infection 1,734
- Headache 1,639
- Feeling sick to your stomach 1,386
- Low red blood cell count 1,185
Darunavir can cause liver problems. Your doctor should check your liver before you start taking darunavir and during treatment. Tell your doctor right away if you have any signs of liver problems, such as yellowing of the skin or eyes.
Vosevi can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Before starting Vosevi, your doctor will test you for Hepatitis B. They will also monitor you during and after treatment.
Tell your doctor if you are pregnant or plan to become pregnant. The recommended dose during pregnancy is 600 mg twice daily with ritonavir 100mg and food. Women with HIV should not breastfeed because HIV can be passed to the baby through breast milk.
It is not known if Vosevi can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Vosevi passes into breast milk, so discuss this with your doctor if you are breastfeeding.
How to Read This darunavir vs sofosbuvir/velpatasvir Comparison
darunavir is classified in the HIV Protease Inhibitor drug class, while sofosbuvir/velpatasvir sits within the NS5B/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, darunavir has 4,643 submissions while sofosbuvir/velpatasvir has 8,251. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to research indicates that there is no important interaction between these two medications. they do not interfere with each other's levels in the blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for darunavir or sofosbuvir/velpatasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.